Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Quarterly Report · 10-Q

OraSure Technologies, Inc.

OSURNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 7, 2026Accepted Aug 7, 2026, 4:04 PM EDTCIK 1116463Accession 0001116463-26-000052
Share

Company context

OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc., Sherlock Biosciences, Inc., and BioMedomics, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physicians’ offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com

Current securities

Recent company filings

  1. SCHEDULE 13D filingSep 17, 2026
  2. SCHEDULE 13G filingAug 12, 2026
  3. S-8 filingAug 7, 2026
  4. Results of Operations and Financial ConditionAug 5, 2026
  5. SCHEDULE 13G/A filingJul 31, 2026

As-filed source

Primary evidence